Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
Want to see MRVI full AI Analyst Report?
MRVI Stock Chart & Stats
$3.39
$0.02(0.33%)
At close: 4:00 PM EST
$3.39
$0.02(0.33%)
Day’s Range― - ―
52-Week Range$1.95 - $5.00
Previous CloseN/A
Volume457.32K
Average Volume (3M)1.73M
Market Cap
$1.10B
Enterprise Value$1.02B
Total Cash (Recent Filing)$165.92M
Total Debt (Recent Filing)$35.31M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding146,383,160
10 Day Avg. Volume1,932,683
30 Day Avg. Volume1,726,279
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.96
Enterprise Value/Gross Profit17.11
Enterprise Value/Ebitda-10.09
Forecast
1Y Price Target
$4.82Price Target Upside42.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$210.80M
Bulls Say, Bears Say
Bulls Say
Growth GuidanceCompany provided forward guidance implying modest growth across nucleic acid production and biologics testing, offering a clearer path to top-line recovery and positive cash flow if projections are met.
Margin ExpansionRestructuring and cost-reduction efforts improved gross margins and lowered fixed costs, enhancing profitability per unit and reducing sensitivity to demand swings.
Operational RestructuringManagement's restructuring and centralized operations strengthened internal controls and commercial capabilities, supporting stabilization of the business and improved customer engagement.
Bears Say
Market ExposureOngoing exposure to a challenging market and partial dependence on pandemic-era products creates revenue risk if demand for those products weakens.
Revenue VolatilityUneven segment performance and the disappearance of a large one-time order highlight volatility in revenue streams and raise questions about sustainable growth.
Maravai Lifesciences Holdings News
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $1.95 and its highest was $5.00 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Maravai Lifesciences Holdings’s market cap is $1.10B.
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Aug 11, 2026 which is in 87 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on May 07, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.047 by $0.057.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is -0.05.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 146,383,160 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.047. Following the earnings report the stock price went up 23.096%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Currently, no hedge funds are holding shares in MRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maravai Lifesciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.82 (42.28% Upside)
$4.82 (42.28% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.87%
12-Months-Change
Fundamentals
Return on Equity
-44.72%
Trailing 12-Months
Asset Growth
-25.69%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
MRVI Company Deck
MRVI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial progress: robust revenue growth (41% YoY), sizable adjusted EBITDA improvement, first positive free cash flow since 2024, raised full-year revenue and EBITDA guidance, product adoption (ModTail) and R&D/IP milestones. Challenges discussed were largely execution and timing related (China/distributor ordering, quarter-to-quarter lumpiness, academic demand weakness) and some near-term limitations from new GMP launches and elevated debt. Overall, positives—driven by mix shift toward higher-margin GMP/discovery consumables, realized cost savings, and improving cash generation—outweigh the highlighted risks.View all MRVI earnings summariesMRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
MRVI Stock 12 Month Forecast
Average Price Target
$4.82
▲(42.28% Upside)
Technical Analysis
Ownership Overview
4.81% Insiders
14.07% Mutual Funds
16.17% Other Institutional Investors
53.82% Public Companies and
Individual Investors